UNICREDIT BANK/PUT/VERTEX PHARMACEUTICALS/500/0.1/18.09.24 Stock UNICREDIT BANK/PUT/VERTEX PHARMACEUTICALS/500/0.1/18.09.24
Add to a list
To use this feature you must be a member
Log inSign up

UNICREDIT BANK/PUT/VERTEX PHARMACEUTICALS/500/0.1/18.09.24 Share Price

Warrant

DE000HD68A49

Real-time BOERSE MUENCHEN 10:41:41 05/07/2024 BST
3.39 EUR -0.29% Intraday chart for UNICREDIT BANK/PUT/VERTEX PHARMACEUTICALS/500/0.1/18.09.24
Current month+0.29%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart VERTEX PHARMACEUTICALS INCORPORATED
Chart UNICREDIT BANK/PUT/VERTEX PHARMACEUTICALS/500/0.1/18.09.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis MT
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy DJ
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis BU
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment for Cystic Fibrosis CI
More news

Quotes 5-day view

Date Price Change
05/07/24 3.39 -0.29%
04/07/24 3.4 0.00%
03/07/24 3.4 +4.94%
02/07/24 3.24 -4.14%
01/07/24 3.38 -0.29%

Real-time BOERSE MUENCHEN

Last update July 05, 2024 at 10:41 am

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying VERTEX PHARMACEUTICALS INCORPORATED
IssuerLogo Issuer UniCredit UniCredit
WKN HD68A4
ISINDE000HD68A49
Date issued 10/06/2024
Strike 500 $
Maturity 18/09/2024 (76 Days)
Parity 10 : 1
Emission price 3.15 €
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 3.88 €
Lowest since issue 2.96 €
Delta-0.65x
Omega 8.301
Premium1.46x
Gearing12.85x
Moneyness 1.063
Difference Strike 29.72 $
Difference Strike %+5.94%
Spread 0.14 €
Spread %4.06%
Theoretical value 3.390
Implied Volatility 25.80 %
Total Loss Probability 31.23 %
Intrinsic value 2.745
Present value 0.6449
Break even 463.30 €
Theta-0.06x
Vega0.07x
Rho-0.06x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
470.3 USD
Average target price
468.3 USD
Spread / Average Target
-0.43%
Consensus
  1. Stock Market
  2. Warrants
  3. Warrant